These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 27600563

  • 1. Diagnosis and treatment of Paget's disease of bone : A clinical practice guideline.
    Muschitz C, Feichtinger X, Haschka J, Kocijan R.
    Wien Med Wochenschr; 2017 Feb; 167(1-2):18-24. PubMed ID: 27600563
    [Abstract] [Full Text] [Related]

  • 2. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
    Al Nofal AA, Altayar O, BenKhadra K, Qasim Agha OQ, Asi N, Nabhan M, Prokop LJ, Tebben P, Murad MH.
    Osteoporos Int; 2015 Jul; 26(7):1875-91. PubMed ID: 26037791
    [Abstract] [Full Text] [Related]

  • 3. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
    Alvarez L, Guañabens N, Peris P, Vidal S, Ros I, Monegal A, Bedini JL, Deulofeu R, Pons F, Muñoz-Gomez J, Ballesta AM.
    Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
    [Abstract] [Full Text] [Related]

  • 4. Two cases of monostotic Paget's disease: effects of bisphosphonate.
    Hoshiro M, Harada T, Iwai H, Miyatake T, Nishimura A, Ohno Y, Aoki N.
    Endocr J; 2003 Aug; 50(4):385-92. PubMed ID: 14599111
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Paget's disease of bone: an endocrine society clinical practice guideline.
    Singer FR, Bone HG, Hosking DJ, Lyles KW, Murad MH, Reid IR, Siris ES, Endocrine Society.
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4408-22. PubMed ID: 25406796
    [Abstract] [Full Text] [Related]

  • 10. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone.
    Garnero P, Christgau S, Delmas PD.
    Bone; 2001 May; 28(5):461-4. PubMed ID: 11344044
    [Abstract] [Full Text] [Related]

  • 11. Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone.
    Reid IR, Maslowski K.
    Calcif Tissue Int; 2017 Jul; 101(1):43-49. PubMed ID: 28324123
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A.
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [Abstract] [Full Text] [Related]

  • 14. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P, Alvarez L, Vidal S, Martínez MA, Monegal A, Guañabens N.
    Clin Exp Rheumatol; 2007 Mar; 25(2):206-10. PubMed ID: 17543143
    [Abstract] [Full Text] [Related]

  • 15. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
    de la Piedra C, Rapado A, Díaz Diego EM, Díaz Martín MA, Aguirre C, López Gavilanes E, Díaz Curiel M.
    Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
    [Abstract] [Full Text] [Related]

  • 16. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D.
    N Engl J Med; 2005 Sep 01; 353(9):898-908. PubMed ID: 16135834
    [Abstract] [Full Text] [Related]

  • 17. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR.
    J Bone Miner Res; 2007 Jan 01; 22(1):142-8. PubMed ID: 17032148
    [Abstract] [Full Text] [Related]

  • 18. Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement.
    Peris P, Alvarez L, Vidal S, Kasper D, Leeming DJ, Monegal A, Angeles Martínez M, Pons F, Guañabens N.
    Calcif Tissue Int; 2006 Jul 01; 79(1):22-6. PubMed ID: 16868670
    [Abstract] [Full Text] [Related]

  • 19. Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone.
    Ohara M, Imanishi Y, Nagata Y, Ishii A, Kobayashi I, Mori K, Ito M, Miki T, Nishizawa Y, Inaba M.
    J Bone Miner Metab; 2015 Sep 01; 33(5):584-90. PubMed ID: 25319558
    [Abstract] [Full Text] [Related]

  • 20. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone.
    Arden-Cordone M, Siris ES, Lyles KW, Knieriem A, Newton RA, Schaffer V, Zelenakas K.
    Calcif Tissue Int; 1997 May 01; 60(5):415-8. PubMed ID: 9115157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.